Joshua Zeidner, MD

Explore evolving CML therapy choices, from mutation-guided second-line switches to asciminib, as clinicians aim for durable, treatment-free remission.

How CML doctors plan treatment-free remission from day one, aiming for MR4.5, boosting adherence, and timing TKI stopping to reduce relapse.

Experts weigh CML PCR milestones, urging context over rigid cutoffs when switching TKIs—and keeping treatment‑free remission goals in sight.

Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission.

Asciminib reshapes frontline CML care with fewer side effects and deeper molecular responses, while clinicians watch long-term safety and TFR results

Dr. Zeidner explores frontline treatment selection strategies, emphasizing the abundance of oral options available at diagnosis and sequencing possibilities throughout patient treatment courses.

Dr. Joshua Zeidner from University of North Carolina Lineberger Comprehensive Cancer Center and Dr. Jorge Cortes from O'Neal Cancer Center at University of Alabama Birmingham introduce their discussion on frontline chronic myeloid leukemia (CML) management.